What does PHARMAKES do?

PHARMAKES is a pharmacy in Ieper. Private Limited, started on 3 May 2012, 1 establishment.

What is the address of PHARMAKES?

The registered office of PHARMAKES is located at Izegrimstraat 4, 8900 Ieper.

Is PHARMAKES still active?

Yes. According to the CBE (30 October 2026) PHARMAKES is active, legal situation “Normale toestand”, started on 3 May 2012.

Is PHARMAKES registered on Peppol?

Yes, PHARMAKES is registered on the Peppol network with ID 0208:0845691926.

What is the enterprise number of PHARMAKES?

The enterprise number of PHARMAKES is BE0845691926.

When was PHARMAKES founded?

PHARMAKES was founded on 3 May 2012.

Who are the directors of PHARMAKES?

According to the 2025 annual accounts, the directors of PHARMAKES are: Roel Kestelyn.

Is PHARMAKES a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 3 May 2012; 4 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

How much profit did PHARMAKES make in 2025?

PHARMAKES posted a profit after taxes of € 32,749 in financial year 2025.

What is the revenue of PHARMAKES?

As a small company, PHARMAKES is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 95,565.

How many employees does PHARMAKES have?

According to the 2025 annual accounts, PHARMAKES has 0 full-time equivalents (FTE).

PHARMAKES (Private Limited) - Ieper - BE0845691926

Dossier PHARMAKES, printed on 30 October 2026 from databakkes.be/en/0845691926/pharmakes. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

PHARMAKES from Ieper, company number BE0845691926, closed financial year 2025 with a result of € 32,749 after tax. For that financial year PHARMAKES recorded a gross margin of € 95,565 and equity of € 1.2 million. Compared with financial year 2024, the result moved from € 110,072 to € 32,749. The company is profitable. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on October 31, 2025.

What it is worth Growing

€ 1.2 million

▲ 3% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Healthy

€ 32,749

▼ 70% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 15,160

▼ 94% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Growing

Stays in the company

No dividend for 2025. Retained profit grew to € 1.2 million.

People and assets in 2025

Full-time equivalents

Average over the fiscal year, from the social balance sheet.

Vehicles and equipment

€ 43,895

▼ 22% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt ≈ 8 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 544,490

▼ 11% vs 2024

€ 71,430 is repaid this year. At this pace the long-term loan is gone in ≈ 8 years.

Owed to suppliers

€ 1,341

▲ 143% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 6,806

▼ 63% vs 2024

Taxes, VAT and social contributions still to pay.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 359,174 Gross margin 2022: € 359,174 First fiscal year in the series	€ 477,209 Gross margin 2023: € 477,209 ▲ 33% vs 2022 (€ 359,174) Favourable step	€ 220,256 Gross margin 2024: € 220,256 ▼ 54% vs 2023 (€ 477,209) Unfavourable step	€ 95,565 Gross margin 2025: € 95,565 ▼ 57% vs 2024 (€ 220,256) Unfavourable step	▼ 57%
Profit after taxes	€ 203,080 Profit after taxes 2022: € 203,080 First fiscal year in the series	€ 283,001 Profit after taxes 2023: € 283,001 ▲ 39% vs 2022 (€ 203,080) Favourable step	€ 110,072 Profit after taxes 2024: € 110,072 ▼ 61% vs 2023 (€ 283,001) Unfavourable step	€ 32,749 Profit after taxes 2025: € 32,749 ▼ 70% vs 2024 (€ 110,072) Unfavourable step	▼ 70%
Equity	€ 764,431 Equity 2022: € 764,431 First fiscal year in the series	€ 1,047,432 Equity 2023: € 1,047,432 ▲ 37% vs 2022 (€ 764,431) Favourable step	€ 1,156,670 Equity 2024: € 1,156,670 ▲ 10% vs 2023 (€ 1,047,432) Favourable step	€ 1,189,419 Equity 2025: € 1,189,419 ▲ 3% vs 2024 (€ 1,156,670) Favourable step	▲ 3%
Total debts	€ 821,099 Total debts 2022: € 821,099 First fiscal year in the series	€ 1,196,690 Total debts 2023: € 1,196,690 ▲ 46% vs 2022 (€ 821,099) Unfavourable step	€ 882,091 Total debts 2024: € 882,091 ▼ 26% vs 2023 (€ 1,196,690) Favourable step	€ 553,904 Total debts 2025: € 553,904 ▼ 37% vs 2024 (€ 882,091) Favourable step	▼ 37%
Cash	€ 277,696 Cash 2022: € 277,696 First fiscal year in the series	€ 486,813 Cash 2023: € 486,813 ▲ 75% vs 2022 (€ 277,696) Favourable step	€ 239,171 Cash 2024: € 239,171 ▼ 51% vs 2023 (€ 486,813) Unfavourable step	€ 15,160 Cash 2025: € 15,160 ▼ 94% vs 2024 (€ 239,171) Unfavourable step	▼ 94%
Retained profit	€ 745,831 Retained profit 2022: € 745,831 First fiscal year in the series	€ 1,028,832 Retained profit 2023: € 1,028,832 ▲ 38% vs 2022 (€ 745,831) Favourable step	€ 1,138,070 Retained profit 2024: € 1,138,070 ▲ 11% vs 2023 (€ 1,028,832) Favourable step	€ 1,170,819 Retained profit 2025: € 1,170,819 ▲ 3% vs 2024 (€ 1,138,070) Favourable step	▲ 3%
Dividend	€ 0 Dividend 2022: € 0 First fiscal year in the series	€ 0 Dividend 2023: € 0 Unchanged (€ 0) Unchanged	€ 834 Dividend 2024: € 834 Unchanged (€ 0) Unchanged	€ 0 Dividend 2025: € 0 ▼ 100% vs 2024 (€ 834) Unchanged	▼ 100%
Bank debt	€ 771,660 Bank debt 2022: € 771,660 First fiscal year in the series	€ 716,071 Bank debt 2023: € 716,071 ▼ 7% vs 2022 (€ 771,660) Favourable step	€ 612,604 Bank debt 2024: € 612,604 ▼ 14% vs 2023 (€ 716,071) Favourable step	€ 544,490 Bank debt 2025: € 544,490 ▼ 11% vs 2024 (€ 612,604) Favourable step	▼ 11%
Balance sheet total	€ 1,585,530 Balance sheet total 2022: € 1,585,530 First fiscal year in the series	€ 2,244,122 Balance sheet total 2023: € 2,244,122 ▲ 42% vs 2022 (€ 1,585,530) Unchanged	€ 2,038,761 Balance sheet total 2024: € 2,038,761 ▼ 9% vs 2023 (€ 2,244,122) Unchanged	€ 1,743,323 Balance sheet total 2025: € 1,743,323 ▼ 14% vs 2024 (€ 2,038,761) Unchanged	▼ 14%

Key figures of PHARMAKES, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 October 2026.

What happened to PHARMAKES?

What happened at PHARMAKES in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Oct 31, 2025 New annual accounts for financial year 2025: profit of € 32,749 (▼ 70% vs 2024). Source: NBB ↗
May 3, 2012 New establishment in Ieper. KBO
2012 Roel Kestelyn became a director. NBB
May 3, 2012 Start of the company according to the CBE. KBO

In short

From € 203,080 profit in 2022 to € 32,749 profit in 2025.

Paid € 337,447 in corporate taxes since 2022.

Best year ever: 2023, with € 283,001 profit.

Paid out € 834 in dividends to the owners in total.

Original PDFs at the National Bank ↗

Management

Roel Kestelyn

PHARMAKES

Apotheek Kestelyn 99.9%

Behind PHARMAKES is Roel Kestelyn. It owns 99.9% of Apotheek Kestelyn itself.

Directors

According to the 2025 annual accounts

Roel Kestelyn

Director

Also active at: IMMOKES

since 2012

Establishments

Establishment units

Physical locations of this company

Registered office

Izegrimstraat 4

8900 Ieper

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0845.691.926

VAT number

BE 0845.691.926

Registered office

Izegrimstraat 4, 8900 Ieper

Names & denominations

PHARMAKES

Enterprise type

Rechtspersoon

Legal form

Private limited company

Legal situation

Normale toestand

Start date

3 May 2012

Peppol

Active · Active since 19 Mar 2025

Activities · NACE

Detailhandel in farmaceutische producten

Overige zakelijke dienstverlening, neg

View on CBE Public ↗ Annual accounts (NBB) ↗

PHARMAKES

Financials

What happened to PHARMAKES?

Management

Directors

Establishments

Establishment units

Details

Frequently asked questions